Filing Details

Accession Number:
0001127602-21-017683
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-20 18:08:53
Reporting Period:
2021-05-18
Accepted Time:
2021-05-20 18:08:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
313143 Haemonetics Corp HAE Surgical & Medical Instruments & Apparatus (3841) 042882273
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1722327 Dan Goldstein 125 Summer Street
Boston MA 02110
Vp, Corporate Controller No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-05-18 994 $0.00 2,463 No 4 A Direct
Common Stock Disposition 2021-05-19 42 $55.19 2,421 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-qualified Stock Option (Right to Buy) Acquisiton 2021-05-18 2,690 $0.00 2,690 $56.57
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,690 2028-05-18 No 4 A Direct
Footnotes
  1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
  2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
  3. This number includes unvested RSUs previously reported.
  4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  5. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.